Predicting the Efficacy of Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Using an AI Platform Based on Multi-parametric MRI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-24

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Establish a deep learning model based on multi-parameter magnetic resonance imaging to predict the efficacy of neoadjuvant therapy for locally advanced rectal cancer.This study intends to combine DCE with conventional MRI images for DL, establish a multi-parameter MRI model for predicting the efficacy of CRT, and compare it with the DL and non-artificial quantitative MRI diagnostic model constructed by conventional MRI to evaluate the role of DL in MRI predicting CRT. And this study also tries to build a DL platform to assess the efficacy of LARC neoadjuvant radiotherapy and chemotherapy, accurately assess patients' complete respose (pCR) after CRT, and provide an important basis for guiding clinical decision-making.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Neoadjuvant Treatment MRI Based AI System to Predict pCR for Rectal Cancer

NCT04278274

Rectal Cancer

UNKNOWN

Radiomics-based Artificial Intelligence System to Predict Neoadjuvant Treatment Response in Rectal Cancer

NCT04273477

Rectal Cancer

UNKNOWN

Deep Learning Based MRI Radiomics in Predicting the Clinical Risk of Locally Advanced Rectal Cancer

NCT06314750

Locally Advanced Rectal Carcinoma

COMPLETED

RadioPathomics Artificial Intelligence Model to Predict Tumor Regression Grading in Locally Advanced Rectal Cancer

NCT04273451

Rectal Cancer

UNKNOWN

A Study On The Prediction of Neoadjuvant Efficacy For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics

NCT07107815

Rectal Cancer, Adenocarcinoma

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

complete response

Patients receiving neoadjuvant therapy achieved pathological complete response before LARC.

No interventions assigned to this group

non complete response

Patients receiving neoadjuvant therapy did not achieve pathological complete response before LARC.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical suspicion or colonoscopic pathology of rectal cancer
* Age over 18 years
* Informed consent and signed informed consent form

Exclusion Criteria

* Poor magnetic resonance image quality, such as severe artifacts
* Previous treatment for rectal cancer
* History or combination of other malignant tumours
* Not Locally Advanced Rectal Cancer (LARC)
* Not received neoadjuvant therapy or not completed neoadjuvant therapy
* No surgery
* Time interval between MRI and surgery was more than 2 weeks
* Patients were lost to follow-up and voluntarily withdrew from the study due to adverse reactions or other reasons

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No